|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0016011,
umls-concept:C0026336,
umls-concept:C0032143,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0087111,
umls-concept:C0262469,
umls-concept:C0302350,
umls-concept:C0442805,
umls-concept:C0557702,
umls-concept:C0597357,
umls-concept:C1522673,
umls-concept:C1999216
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2003-6-10
|
|
pubmed:abstractText |
Platelet aggregation and fibrin deposition are key events leading to microvascular thrombosis and progressive impairment of downstream microvascular perfusion after stroke. We tested the hypothesis that inhibition of platelet function with a GP IIb/IIIa receptor antagonist would increase the efficacy and safety and increase the time window for thrombolytic therapy for stroke with full- and half-dose tissue plasminogen activator (tPA).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2837-43
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12756151-Animals,
pubmed-meshheading:12756151-Antibodies, Monoclonal,
pubmed-meshheading:12756151-Body Weight,
pubmed-meshheading:12756151-Cerebrovascular Circulation,
pubmed-meshheading:12756151-Chemotherapy, Adjuvant,
pubmed-meshheading:12756151-Disease Models, Animal,
pubmed-meshheading:12756151-Dose-Response Relationship, Drug,
pubmed-meshheading:12756151-Drug Synergism,
pubmed-meshheading:12756151-Fibrinolysis,
pubmed-meshheading:12756151-Immunoglobulin Fab Fragments,
pubmed-meshheading:12756151-Infarction, Middle Cerebral Artery,
pubmed-meshheading:12756151-Infusions, Intravenous,
pubmed-meshheading:12756151-Injections, Intravenous,
pubmed-meshheading:12756151-Intracranial Embolism,
pubmed-meshheading:12756151-Male,
pubmed-meshheading:12756151-Microcirculation,
pubmed-meshheading:12756151-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:12756151-Rats,
pubmed-meshheading:12756151-Rats, Wistar,
pubmed-meshheading:12756151-Recovery of Function,
pubmed-meshheading:12756151-Stroke,
pubmed-meshheading:12756151-Tissue Plasminogen Activator,
pubmed-meshheading:12756151-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
|
|
pubmed:affiliation |
Department of Neurology, Henry Ford Health Sciences Center, Detroit, Mich, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
